Literature DB >> 32959468

Standard procedures for the diagnostic pathway of sleep-related epilepsies and comorbid sleep disorders: A European Academy of Neurology, European Sleep Research Society and International League against Epilepsy-Europe consensus review.

Lino Nobili1,2, Al de Weerd3, Guido Rubboli4,5, Sándor Beniczky6,7,8, Christopher Derry9,10, Sofia Eriksson11, Peter Halasz12, Birgit Högl13, Joan Santamaria14, Ramin Khatami15,16, Philippe Ryvlin17, Jan Rémi18, Paolo Tinuper19,20, Claudio Bassetti21, Raffaele Manni22, Michalis Koutroumanidis23, Luca Vignatelli20.   

Abstract

BACKGROUND: Some epilepsy syndromes (sleep-related epilepsies [SRE]) have a strong link with sleep. Comorbid sleep disorders are common in patients with SRE and can exert a negative impact on seizure control and quality of life. PURPOSES: To define the standard procedures for the diagnostic pathway of patients with possible SRE (scenario 1) and the general management of patients with SRE and comorbidity with sleep disorders (scenario 2).
METHODS: The project was conducted under the auspices of the European Academy of Neurology (EAN), the European Sleep Research Society (ESRS) and the International League against Epilepsy (ILAE) Europe. The framework of the document entailed the following phases: conception of the clinical scenarios; literature review; statements regarding the standard procedures. For literature search a step-wise approach starting from systematic reviews to primary studies was applied. Published studies were identified from the National Library of Medicine's MEDLINE database and Cochrane Library.
RESULTS: Scenario 1: despite a low quality of evidence, recommendations on anamnestic evaluation, tools for capturing the event at home or in the laboratory are provided for specific SRE. Scenario 2: Early diagnosis and treatment of sleep disorders (especially respiratory disorders) in patients with SRE are likely to be beneficial for seizures control.
CONCLUSIONS: Definitive procedures for evaluating patients with SRE are lacking. We provide advice that could be of help for standardising and improving the diagnostic approach of specific SRE. The importance of identifying and treating specific sleep disorders for the management and outcome of patients with SRE is underlined.
© 2020 European Academy of Neurology and European Sleep Research Society.

Entities:  

Keywords:  epilepsy; insomnia; polysomnography; restless legs syndrome; sleep apnea; sleep-related hypermotor epilepsy

Year:  2020        PMID: 32959468     DOI: 10.1111/jsr.13184

Source DB:  PubMed          Journal:  J Sleep Res        ISSN: 0962-1105            Impact factor:   3.981


  5 in total

Review 1.  Disorders of arousal and sleep-related hypermotor epilepsy - overview and challenges night is a battlefield of sleep and arousal promoting forces.

Authors:  Péter Halász; Anna Szűcs; Carlotta Mutti; Liborio Parrino
Journal:  Neurol Sci       Date:  2022-01-05       Impact factor: 3.307

2.  Editorial: Brain Mechanisms Linking Sleep and Epilepsy.

Authors:  Vasileios Kokkinos; Andreas M Koupparis; Michalis Koutroumanidis; George K Kostopoulos
Journal:  Front Hum Neurosci       Date:  2022-05-10       Impact factor: 3.473

Review 3.  Sleep and epilepsy: A snapshot of knowledge and future research lines.

Authors:  Lino Nobili; Birgit Frauscher; Sofia Eriksson; Steve Alex Gibbs; Peter Halasz; Isabelle Lambert; Raffaele Manni; Laure Peter-Derex; Paola Proserpio; Federica Provini; Al de Weerd; Liborio Parrino
Journal:  J Sleep Res       Date:  2022-04-29       Impact factor: 5.296

4.  The additional diagnostic benefits of performing both video-polysomnography and prolonged video-EEG-monitoring: When and why.

Authors:  Melanie Bergmann; Elisabeth Brandauer; Ambra Stefani; Anna Heidbreder; Iris Unterberger; Birgit Högl
Journal:  Clin Neurophysiol Pract       Date:  2022-02-26

Review 5.  The Management and Alternative Therapies for Comorbid Sleep Disorders in Epilepsy.

Authors:  Weifeng Peng; Jing Ding; Xin Wang
Journal:  Curr Neuropharmacol       Date:  2021       Impact factor: 7.363

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.